Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Rights & PermissionsPrintExport